Literature DB >> 20231476

Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine.

Michael T Heneka1, Fabian Nadrigny, Tommy Regen, Ana Martinez-Hernandez, Lucia Dumitrescu-Ozimek, Dick Terwel, Daniel Jardanhazi-Kurutz, Jochen Walter, Frank Kirchhoff, Uwe-Karsten Hanisch, Markus P Kummer.   

Abstract

Locus ceruleus (LC)-supplied norepinephrine (NE) suppresses neuroinflammation in the brain. To elucidate the effect of LC degeneration and subsequent NE deficiency on Alzheimer's disease pathology, we evaluated NE effects on microglial key functions. NE stimulation of mouse microglia suppressed Abeta-induced cytokine and chemokine production and increased microglial migration and phagocytosis of Abeta. Induced degeneration of the locus ceruleus increased expression of inflammatory mediators in APP-transgenic mice and resulted in elevated Abeta deposition. In vivo laser microscopy confirmed a reduced recruitment of microglia to Abeta plaque sites and impaired microglial Abeta phagocytosis in NE-depleted APP-transgenic mice. Supplying the mice the norepinephrine precursor L-threo-DOPS restored microglial functions in NE-depleted mice. This indicates that decrease of NE in locus ceruleus projection areas facilitates the inflammatory reaction of microglial cells in AD and impairs microglial migration and phagocytosis, thereby contributing to reduced Abeta clearance. Consequently, therapies targeting microglial phagocytosis should be tested under NE depletion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20231476      PMCID: PMC2851853          DOI: 10.1073/pnas.0909586107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Co-expression of multiple transgenes in mouse CNS: a comparison of strategies.

Authors:  J L Jankowsky; H H Slunt; T Ratovitski; N A Jenkins; N G Copeland; D R Borchelt
Journal:  Biomol Eng       Date:  2001-06

2.  Impaired recovery of noradrenaline levels in apolipoprotein E-deficient mice after N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine lesion.

Authors:  J Puoliväli; L Pradier; P Riekkinen
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

3.  Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion.

Authors:  S Jung; J Aliberti; P Graemmel; M J Sunshine; G W Kreutzberg; A Sher; D R Littman
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

Review 4.  Current concepts in mild cognitive impairment.

Authors:  R C Petersen; R Doody; A Kurz; R C Mohs; J C Morris; P V Rabins; K Ritchie; M Rossor; L Thal; B Winblad
Journal:  Arch Neurol       Date:  2001-12

5.  Effects of norepinephrine on rat cultured microglial cells that express alpha1, alpha2, beta1 and beta2 adrenergic receptors.

Authors:  Kohji Mori; Emi Ozaki; Bo Zhang; Lihua Yang; Akiko Yokoyama; Ikuko Takeda; Nobuji Maeda; Masahiro Sakanaka; Junya Tanaka
Journal:  Neuropharmacology       Date:  2002-11       Impact factor: 5.250

6.  Noradrenergic changes, aggressive behavior, and cognition in patients with dementia.

Authors:  Kim L Matthews; Christopher P L-H Chen; Margaret M Esiri; Janet Keene; Stephen L Minger; Paul T Francis
Journal:  Biol Psychiatry       Date:  2002-03-01       Impact factor: 13.382

7.  Noradrenergic depletion potentiates beta -amyloid-induced cortical inflammation: implications for Alzheimer's disease.

Authors:  Michael T Heneka; Elena Galea; Vitaliy Gavriluyk; Lucia Dumitrescu-Ozimek; JoAnna Daeschner; M Kerry O'Banion; Guy Weinberg; Thomas Klockgether; Douglas L Feinstein
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

Review 8.  Noradrenergic regulation of inflammatory gene expression in brain.

Authors:  Douglas L Feinstein; Michael T Heneka; Vitaliy Gavrilyuk; Cinzia Dello Russo; Guy Weinberg; Elena Galea
Journal:  Neurochem Int       Date:  2002-11       Impact factor: 3.921

9.  Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases.

Authors:  Chris Zarow; Scott A Lyness; James A Mortimer; Helena C Chui
Journal:  Arch Neurol       Date:  2003-03

10.  The inhibitory effects of interleukin-6 on synaptic plasticity in the rat hippocampus are associated with an inhibition of mitogen-activated protein kinase ERK.

Authors:  V Tancredi; M D'Antuono; C Cafè; S Giovedì; M C Buè; G D'Arcangelo; F Onofri; F Benfenati
Journal:  J Neurochem       Date:  2000-08       Impact factor: 5.372

View more
  165 in total

1.  Beyond amyloid: getting real about nonamyloid targets in Alzheimer's disease.

Authors:  Karl Herrup; Maria C Carrillo; Dale Schenk; Angela Cacace; Susan Desanti; Robert Fremeau; Ratan Bhat; Marcie Glicksman; Patrick May; Russell Swerdlow; Linda J Van Eldik; Lisa J Bain; Samantha Budd
Journal:  Alzheimers Dement       Date:  2013-07       Impact factor: 21.566

2.  Modulation of neuroinflammation and pathology in the 5XFAD mouse model of Alzheimer's disease using a biased and selective beta-1 adrenergic receptor partial agonist.

Authors:  Pooneh Memar Ardestani; Andrew K Evans; Bitna Yi; Tiffany Nguyen; Laurence Coutellier; Mehrdad Shamloo
Journal:  Neuropharmacology       Date:  2017-01-13       Impact factor: 5.250

Review 3.  Turning on the Light Within: Subcortical Nuclei of the Isodentritic Core and their Role in Alzheimer's Disease Pathogenesis.

Authors:  Panos Theofilas; Sara Dunlop; Helmut Heinsen; Lea Tenenholz Grinberg
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

4.  Stress-Induced Alterations of Immune Profile in Animals Suffering by Tau Protein-Driven Neurodegeneration.

Authors:  Petr Novak; Martin Cente; Nina Kosikova; Tomas Augustin; Richard Kvetnansky; Michal Novak; Peter Filipcik
Journal:  Cell Mol Neurobiol       Date:  2017-04-12       Impact factor: 5.046

5.  Amyloid beta peptide-(1-42) induces internalization and degradation of beta2 adrenergic receptors in prefrontal cortical neurons.

Authors:  Dayong Wang; Eunice Y Yuen; Yuan Zhou; Zhen Yan; Yang K Xiang
Journal:  J Biol Chem       Date:  2011-07-11       Impact factor: 5.157

Review 6.  Microglia in Alzheimer's disease.

Authors:  Heela Sarlus; Michael T Heneka
Journal:  J Clin Invest       Date:  2017-09-01       Impact factor: 14.808

7.  Features of the structure, development, and activity of the zebrafish noradrenergic system explored in new CRISPR transgenic lines.

Authors:  Matthew J Farrar; Kristine E Kolkman; Joseph R Fetcho
Journal:  J Comp Neurol       Date:  2018-10-15       Impact factor: 3.215

Review 8.  Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders.

Authors:  Vijay K Ramanan; Andrew J Saykin
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

9.  Transgenic Mice Expressing Human α-Synuclein in Noradrenergic Neurons Develop Locus Ceruleus Pathology and Nonmotor Features of Parkinson's Disease.

Authors:  Laura M Butkovich; Madelyn C Houser; Termpanit Chalermpalanupap; Kirsten A Porter-Stransky; Alexa F Iannitelli; Jake S Boles; Grace M Lloyd; Alexandra S Coomes; Lori N Eidson; Maria Elizabeth De Sousa Rodrigues; Danielle L Oliver; Sean D Kelly; Jianjun Chang; Nora Bengoa-Vergniory; Richard Wade-Martins; Benoit I Giasson; Valerie Joers; David Weinshenker; Malú Gámez Tansey
Journal:  J Neurosci       Date:  2020-08-31       Impact factor: 6.167

Review 10.  Locus Coeruleus Modulates Neuroinflammation in Parkinsonism and Dementia.

Authors:  Filippo Sean Giorgi; Francesca Biagioni; Alessandro Galgani; Nicola Pavese; Gloria Lazzeri; Francesco Fornai
Journal:  Int J Mol Sci       Date:  2020-11-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.